JPMorgan Chase & Co. Boosts Abbott Laboratories (NYSE:ABT) Price Target to $120.00

Abbott Laboratories (NYSE:ABT) had its price target raised by stock analysts at JPMorgan Chase & Co. from $110.00 to $120.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the healthcare product maker’s stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 19.16% from the stock’s current price.

A number of other brokerages have also recently weighed in on ABT. Royal Bank Of Canada restated an “outperform” rating and set a $130.00 price objective on shares of Abbott Laboratories in a research note on Friday. Robert W. Baird assumed coverage on shares of Abbott Laboratories in a research report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 target price for the company. Benchmark dropped their price target on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Leerink Partners reduced their price target on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a research note on Tuesday, April 21st. Finally, UBS Group decreased their price objective on shares of Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating for the company in a report on Monday, April 20th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $118.61.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $100.71 on Friday. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The firm has a market capitalization of $175.41 billion, a price-to-earnings ratio of 32.59, a price-to-earnings-growth ratio of 1.73 and a beta of 0.61. The business has a 50 day simple moving average of $89.89 and a 200 day simple moving average of $102.17.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.65% and a net margin of 11.65%.The firm had revenue of $12.51 billion for the quarter, compared to the consensus estimate of $12.52 billion. During the same quarter in the previous year, the business earned $1.26 EPS. The firm’s revenue for the quarter was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities research analysts anticipate that Abbott Laboratories will post 5.48 EPS for the current year.

Insider Buying and Selling

In other Abbott Laboratories news, Director Daniel J. Starks purchased 10,000 shares of the firm’s stock in a transaction on Monday, April 27th. The shares were purchased at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the transaction, the director owned 6,751,103 shares in the company, valued at $625,489,692.95. This represents a 0.15% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Philip P. Boudreau purchased 2,200 shares of the company’s stock in a transaction on Thursday, April 23rd. The stock was bought at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the acquisition, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at $201,300. This represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. 0.46% of the stock is owned by insiders.

Institutional Investors Weigh In On Abbott Laboratories

Institutional investors and hedge funds have recently modified their holdings of the stock. J. Stern & Co. LLP boosted its position in shares of Abbott Laboratories by 12,439.6% in the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after purchasing an additional 39,005,451 shares during the period. Norges Bank acquired a new stake in Abbott Laboratories during the 4th quarter worth about $2,938,892,000. Arrowstreet Capital Limited Partnership lifted its stake in Abbott Laboratories by 217.0% during the first quarter. Arrowstreet Capital Limited Partnership now owns 5,522,222 shares of the healthcare product maker’s stock valued at $566,967,000 after buying an additional 3,780,402 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of Abbott Laboratories by 303.0% in the first quarter. Assenagon Asset Management S.A. now owns 4,429,571 shares of the healthcare product maker’s stock worth $454,784,000 after buying an additional 3,330,368 shares during the period. Finally, Ninety One UK Ltd acquired a new position in shares of Abbott Laboratories in the fourth quarter worth about $336,815,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott beat Q2 earnings expectations and raised 2026 adjusted EPS guidance to $5.45-$5.60, signaling better profit momentum for the rest of the year. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
• Positive Sentiment: Management pointed to stronger second-half demand across multiple businesses, including nutrition, medical devices, diagnostics, and diabetes care, which supports a faster growth profile. ABT Q2 Earnings Call Flags Stronger Second-Half Setup
• Positive Sentiment: Analysts turned more constructive after the results, with JPMorgan, Citi, Piper Sandler, Wells Fargo, TD Cowen, BTIG, and RBC all lifting targets or reaffirming bullish views. These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.